Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) EBIT: 2014-2025

Historic EBIT for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $12.9 million.

  • Ascendis Pharma A's EBIT rose 112.10% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$156.3 million, marking a year-over-year increase of 54.37%. This contributed to the annual value of -$301.7 million for FY2024, which is 38.44% up from last year.
  • Latest data reveals that Ascendis Pharma A reported EBIT of $12.9 million as of Q3 2025, which was up 121.45% from -$59.9 million recorded in Q2 2025.
  • Ascendis Pharma A's 5-year EBIT high stood at $12.9 million for Q3 2025, and its period low was -$154.2 million during Q1 2023.
  • Its 3-year average for EBIT is -$86.6 million, with a median of -$106.2 million in 2024.
  • Examining YoY changes over the last 5 years, Ascendis Pharma A's EBIT showed a top increase of 112.10% in 2025 and a maximum decrease of 105.32% in 2025.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's EBIT stood at -$128.8 million in 2021, then dropped by 16.76% to -$150.4 million in 2022, then spiked by 73.80% to -$39.4 million in 2023, then spiked by 101.04% to $409,272 in 2024, then soared by 112.10% to $12.9 million in 2025.
  • Its EBIT was $12.9 million in Q3 2025, compared to -$59.9 million in Q2 2025 and -$109.6 million in Q1 2025.